Toby Ferguson Net Worth

What's Toby Ferguson's mailing address?

Toby's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Voyager Therapeutics Inc

Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1, eBiosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.

What does Voyager Therapeutics Inc do?

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.

Voyager Therapeutics Inc executives and stock owners

Voyager Therapeutics Inc executives and other stock owners filed with the SEC include:

• Omar Khwaja,
  Chief Medical Officer and Head of Research and Development
• Robert Hesslein,
  Senior Vice President, General Counsel
• G. Andre Turenne,
  President, Chief Executive Officer, Director
• G. Andre Turenne,
  Advisor
• Dr. Omar Khwaja M.D., Ph.D.,
  Chief Medical Officer and Head of R&D
• Robert W. Hesslein,
  Sr. VP & Gen. Counsel
• james Geraghty,
  Independent Director
• Steven Hyman,
  Independent Director
• Michael J. Higgins M.B.A.,
  Interim CEO, Pres & Chairman
• Dr. Glenn F. Pierce M.D., Ph.D.,
  Independent Director, Interim Chief Scientific Officer & Chief Medical Officer
• Dr. Steven M. Paul M.D.,
  Exec. Science Advisor & Director
• Nancy Vitale,
  Director
• Michelle Smith,
  Chief Human Resource Officer
• Kelly Bales,
  Senior Vice President, Head of Neuroscience
• Allison Dorval,
  Chief Financial Officer
• Robin Swartz,
  Chief Operating Officer
• Dr. Alfred W. Sandrock Jr., M.D., Ph.D.,
  Pres, CEO & Director
• Julie Burek,
  VP of Fin.
• Dr. Mark A. Kay M.D., Ph.D.,
  Founder
• Dr. Phillip D. Zamore,
  Founder
• Dr. Mark A. Kay,
  Founder
• Dr. Guangping Gao,
  Founder
• Dr. Krystof Bankiewicz M.D., Ph.D.,
  Founder
• Toby Ferguson,
  Chief Medical Officer
• Sandell Jacquelyn Fahey,
  Chief Legal Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Jane Henderson,
  Sr. V.P. & CFO, Corp. Dev.
• Wendy L Dixon,
  Director
• Jeff Goater,
  Chief Financial Officer
• Sanofi,
  
• Perry A Karsen,
  Director
• Harbor Master Investors (Ca...,
  10% owner
• Bernard Ravina,
  Chief Medical Officer
• Matthew P. Ottmer,
  Chief Operating Officer
• Dinah Ph.D. Sah,
  Chief Scientific Officer
• Steven M Paul,
  Director
• Andre Turenne,
  President & CEO
• Robin Swartz,
  Chief Operating Officer
• Biosciences Inc Neurocrine,
  10% owner
• Michael J Higgins,
  Director
• Mark J Levin,
  Director
• Glenn Pierce,
  Director
• Julie Burek,
  VP, Finance
• Todd Alfred Carter,
  Chief Scientific Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Catherine J Mackey,
  Director
• Jude Onyia,
  Director
• Grace Colon,
  Director
• Capital, Llc Eco R1,
  10% owner
• George A Scangos,
  Director
• Nathan D. Jorgensen,
  Chief Financial Officer